House of Lords Business
Show full summary

Lord Hunt of Kings Heath to ask Her Majesty's Government what assessment they have made of whether liothyronine should be declassified as a high-cost medicine following the Competition and Markets Authority ruling and fine issued to Advanz for artificially inflating the price of thyroid tablets.  HL3198

Question HL3198: tabled on 19 October 2021 and due for answer by 2 November 2021

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Lord Hunt of Kings Heath to ask Her Majesty's Government what assessment they have made of whether liothyronine should be declassified as a high-cost medicine following the Competition and Markets Authority ruling and fine issued to Advanz for artificially inflating the price of thyroid tablets.  HL3198
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Lord Hunt of Kings Heath
Labour
Life peer